TAK-653

DRUG3 trials

Sponsors

Neurocrine Biosciences, Millennium Pharmaceuticals, Inc.

Conditions

Depressive DisorderHealthy VolunteersTreatment-Resistant Depression

Phase 1

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

CompletedNCT02561156

Neurocrine BiosciencesDepressive Disorder

Start: 2015-08-26End: 2017-09-23Updated: 2021-03-03

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

CompletedNCT03792672

Neurocrine BiosciencesHealthy Volunteers

Start: 2019-02-11End: 2019-06-18Updated: 2021-03-19

Phase 2

Efficacy and Safety of TAK-653 in Treatment-Resistant Depression

WithdrawnNCT03312894

Millennium Pharmaceuticals, Inc.Treatment-Resistant Depression

Start: 2018-02-15End: 2019-09-30Updated: 2018-02-22